Celldex Therapeutics Inc
F:TCE2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Celldex Therapeutics Inc
F:TCE2
|
US |
Celldex Therapeutics Inc
Celldex Therapeutics is a biotechnology company that develops antibody-based medicines, mainly for diseases driven by the immune system. Its research focuses on conditions such as allergic and inflammatory disorders, and it also has programs in oncology. The company is not a drug store or manufacturer; it is a drug developer that designs candidates, tests them in clinical trials, and tries to turn promising science into approved treatments. Because Celldex is still a development-stage biotech, it does not sell a broad portfolio of marketed drugs. Instead, it makes money mainly through research funding, collaboration deals, and potential milestone or licensing payments tied to its drug programs. If a medicine wins approval, the long-term value would come from selling or partnering that treatment for use by doctors and patients. What makes Celldex different is its focus on immune targets that can calm overactive disease pathways, especially in allergy and inflammation. That puts it in the high-risk, high-reward part of biotech: the company’s value depends on its patents, lab data, and clinical trial results rather than factories, stores, or large recurring product sales.
Celldex Therapeutics is a biotechnology company that develops antibody-based medicines, mainly for diseases driven by the immune system. Its research focuses on conditions such as allergic and inflammatory disorders, and it also has programs in oncology. The company is not a drug store or manufacturer; it is a drug developer that designs candidates, tests them in clinical trials, and tries to turn promising science into approved treatments.
Because Celldex is still a development-stage biotech, it does not sell a broad portfolio of marketed drugs. Instead, it makes money mainly through research funding, collaboration deals, and potential milestone or licensing payments tied to its drug programs. If a medicine wins approval, the long-term value would come from selling or partnering that treatment for use by doctors and patients.
What makes Celldex different is its focus on immune targets that can calm overactive disease pathways, especially in allergy and inflammation. That puts it in the high-risk, high-reward part of biotech: the company’s value depends on its patents, lab data, and clinical trial results rather than factories, stores, or large recurring product sales.
Cash Position: Celldex ended 2021 with $408 million in cash, providing a runway through 2025.
Lead Program Progress: CDX-0159, their mast cell depleting antibody, showed strong Phase 1 results in chronic inducible urticaria, with a 95% complete response rate and 100% overall response after a single dose.
Subcutaneous Formulation: Positive Phase 1 data for subcutaneous CDX-0159 demonstrated favorable safety, no injection site reactions, and comparable pharmacodynamics to IV dosing.
Phase 2 Readiness: Phase 2 studies in chronic spontaneous and inducible urticaria are on track to start in Q2 2022, supported by successful completion of preclinical toxicology studies.
Pipeline Expansion: Development expanded to a fourth indication, eosinophilic esophagitis (EoE), with a Phase 2 study set to begin in Q4 2022.
Safety Data: Toxicology studies in primates showed only expected reversible effects on spermatogenesis with no female reproductive findings; safety profile remains favorable.
Other Programs: Oncology candidates CDX-1140 and CDX-527 continue to enroll patients, with updates expected later in 2022.
